Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACORQ

Acorda Therapeutics (ACORQ) Stock Price, News & Analysis

Acorda Therapeutics logo

About Acorda Therapeutics Stock (NASDAQ:ACORQ)

Advanced Chart

Key Stats

Today's Range
$0.01
$0.01
50-Day Range
$0.01
$0.06
52-Week Range
$0.01
$18.00
Volume
N/A
Average Volume
67,585 shs
Market Capitalization
$12.42 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ACORQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACORQ Stock News Headlines

Ex-PNP chief Acorda denies POGO involvement
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

Company Calendar

Today
7/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ACORQ
CIK
1008848
Employees
102
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$252.85 million
Net Margins
-227.75%
Pretax Margin
-263.21%

Debt

Sales & Book Value

Annual Sales
$117.63 million
Price / Cash Flow
N/A
Book Value
($127.17) per share
Price / Book
0.00

Miscellaneous

Free Float
1,210,000
Market Cap
$12.42 thousand
Optionable
N/A
Beta
1.67
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ACORQ) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners